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Abstract
Background: Cigarette smoking enhances the risk of stroke. However, the underlying molecular mechanisms are
largely unknown. The present study established an in vivo rat secondhand cigarette smoking (SHS) model and
examined the hypothesis that SHS upregulates endothelin receptors with increased cerebrovascular contraction via
the Raf/extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinases (MAPK) pathway.
Results: Rats were exposed to SHS for up to 8 weeks. The cerebral artery vasoconstriction was recorded by a sensitive
myograph. The mRNA and protein expressions for endothelin receptors in cerebral arteries were studied by real-time
PCR and Western blot. Compared to fresh air exposed rats, cerebral arteries from SHS rats exhibited stronger contractile
responses (P < 0.05) mediated by endothelin type A (ETA) receptors. The expressions of mRNA and protein for ETA
receptors in the cerebral arteries from SHS rats were higher (P < 0.05) than that in control. SHS did not affect endothelin
type B (ETB) receptor-mediated contractions, mRNA or protein levels. The results suggest that SHS upregulates ETA,b u t
not ETB receptors in vivo. After SHS exposure, the mRNA levels of Raf-1 and ERK1/2, the protein expression of
phosphorylated (p)-Raf-1 and p-ERK1/2 were increased (P < 0.05). Raf-1 inhibitor, GW5074 suppressed the enhanced ETA
receptor-mediated contraction, mRNA and protein levels induced by SHS. In addition, GW5074 inhibited the SHS-
caused increased mRNA and phosphorylated protein levels of Raf-1 and ERK1/2, suggesting that SHS induces activation
of the Raf/ERK/MAPK pathway.
Conclusions: SHS upregulates cerebrovascular ETA receptors via the Raf/ERK/MAPK pathway, which provides novel
understanding of mechanisms involved in SHS-associated stroke.
Background
Passive smoke exposure or secondhand smoke (SHS) is
strongly associated with ischemic and hemorrhagic stroke
[1], and has harmful effects on the structure and function
of cerebral blood vessels, promoting atherosclerosis and
stiffening of arteries [2]. However, the biological basis of
SHS on the vessel walls is not well understood.
Endothelin (ET)-1 is one of the most potent vasocon-
striction found in the circulation with elevated levels in
stroke [3]. ET-1 is produced by endothelial cells, mediates
its vasomotor response through two different G-protein
coupled receptors, the endothelin type A (ETA)a n dt h e
endothelin type B (ETB) receptor [4]. In cerebral vessels,
the ETA receptors are found mainly on the smooth muscle
cells and mediate strong vasoconstriction [3], while ETB
receptors are primarily situated on the endothelium of cer-
ebral vessels and stimulate the formation of nitric oxide
and prostacyclin mediating vasodilatation [5]. Because ET-
1 causes potent and long-lasting vasoconstriction, and
there are increased levels of ET-1 in cerebral spinal fluid
(CSF) after subarachnoid hemorrhage (SAH) [6,7]; it has
been suggested to play an important role in the pathogen-
esis of delayed cerebral vasospasm following SAH [8] and
in cerebral ischemia [9]. In addition, there are increasing
evidences demonstrating that experimental SAH and cere-
bral ischemia may be associated with ET receptor upregu-
lation in cerebral artery smooth muscle cells [10,11].
The main risk factors for stroke in general include
hyperlipidemia, hypertension and cigarette smoking [12].
Here we address in particular one of these, SHS, which is
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stroke in general population [13]. Our previous in vitro
studies have demonstrated that lipid-soluble smoke parti-
cles, but not water soluble smoke particles or nicotine per
se,i n d u c eE T B receptor upregulation in cerebral vessels
[14]. The increased receptors result in enhanced contrac-
tility and local inflammation. To the best of our knowl-
edge, it has not been studied if SHS in vivo is associated
with elevated expression of ET receptors. If both the for-
mation of ET-1 and the number of contractile ET recep-
tors are increased in individuals after exposure to SHS, it
may bring about larger damage in SAH or cerebral
infarct, compared to the non-smokers. We hypothesize
that SHS exposure in vivo upregulates ET receptors in
cerebral arteries, which may in turn contribute to larger
brain damage in stroke among smoke exposed subjects.
The cellular mechanisms involved in SHS-associated
s t r o k ea r eu n c l e a r ;h e r ew ee x a m i n ei ft h eE Tr e c e p t o r
upregulation induced by SHS is associated with intracel-
lular mitogen-activated protein kinase (MAPK) signaling.
This system consists of extracellular signal-regulated pro-
tein kinase 1 and 2 (ERK1/2), c-Jun N-terminal kinase
(JNK) and p38 pathways. Raf-1 is the initial protein
kinase in the MAPK signal transduction pathway which
phosphorylates subsequent MAP kinase/extracellular sig-
nal-regulated kinase kinase 1 and 2 (MEK1/2) [15]. We
have recently in detail described that activation of
MAPK-mediated signal transduction is associated with
upregulation of ET receptors in cerebral vasculature and
that ET receptor expression is enhanced in ischemic
stroke [3]. The importance of MAPK signaling in the
pathophysiology of ischemic stroke has been widely stu-
died. Increased ERK1/2 phosphorylation has been
observed in the ischemic area after both transient and
permanent middle cerebral occlusion, as well as after glo-
bal ischemia [16,17]. Consequently, inhibitors of ERK1/2
and MEK1/2 have been effective in reducing the infarct
size in cerebral ischemia [18,19], and in SAH [20]. ERK1/
2 is also activated in the cerebral arteries of the ischemic
brain, pointing towards a role in vascular alterations [21].
However, it is not known if the risk factor SHS per se
may alter ET receptor expression in cerebral arteries and
if this is associated with intracellular signaling via the
Raf/ERK/MAPK pathway.
The present study was designed, using an in vivo rat pas-
sive smoke exposure model, to demonstrate that cigarette
smoke may upregulate cerebrovascular ET receptors, and
to examine the intracellular signal mechanisms of SHS-
induced enhanced ET receptor expression by in vivo treat-
ment with a specific Raf-1 inhibitor.
Results
General
There was no significant difference in cerebral artery
contractile responses to K
+, sarafotoxin 6 c (S6c) and
ET-1 after 2 or 4 weeks in SHS exposed rats as com-
pared to rats exposed to fresh air for a similar time per-
iod (Table 1). Therefore, we only present detailed
results from the 8 weeks of exposure to SHS.
Effects of SHS on ET receptor-mediated contractions in
cerebral artery
The contraction elicited by K
+ w a su s e da sar e f e r e n c e
for the contractile capacity. K
+- induced contractile
responses did not differ significantly in artery segments
from fresh air, SHS and SHS plus inhibitor groups
(Table 2). The ETB receptor-mediated contraction was
examined using the specific ETB receptor agonist S6c,
which has been characterized in detail before using the
ETB receptor antagonist IRL2500 [22]. The vasoconstric-
tion induced by a combined ETA and ETB receptor ago-
nist ET-1 was studied after desensitizing the ETB
receptors with S6c prior to adding ET-1, leaving only
ETA receptors to respond. This has been verified by use
of the selective ETA receptor antagonist FR139317
[22,23].
S 6 co n l yi n d u c e das l i g h tc o n t r a c t i o n( <1 0 %o fK
+-
induced contraction) in cerebral arteries of fresh air
exposed rats. There was no significant difference in S6c-
induced contractions between SHS and fresh air groups
(Figure 1A). After desensitization of ETB receptors, cumu-
lative administration of ET-1 induced potent contraction
of fresh arteries in a concentration-dependent manner (Fig-
ure 1B) with an Emax of 124 ± 9%. Following SHS the
concentration-response curve showed an increased Emax
(160 ± 11%; P < 0.05) with no significant difference in
pEC50 values (Table 2). This indicates that the efficacy of
the response is increased after SHS exposure.
Table 1 Time course of SHS on rat cerebral artery contractions induced by K
+, S6c and ET-1
Exposure time (week) Group n K
+ (mN) S6c
(Emax %o fK
+)
ET-1
(Emax %o fK
+)
2 Fresh air 4 5.6 ± 0.58 8.5 ± 0.9 127 ± 14
SHS 3 5.8 ± 0.63 8.3 ± 1.0 132 ± 15
4 Fresh air 4 5.4 ± 0.52 8.9 ± 1.1 131 ± 17
SHS 4 6.2 ± 0.69 9.1 ± 1.3 136 ± 19
The cerebral arteries were from groups of fresh air and SHS for 2 and 4 weeks. K
+-induced responses were expressed as absolute values of contraction (mN). S6c
and ET-1-induced responses were expressed as percentage of K
+-induced contraction. Emax, maximal contraction; SHS, secondhand smoke exposure.
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expressions
The mRNA and protein levels of ETB and ETA receptors
in cerebral arteries were measured by real-time PCR and
Western blot, respectively. The standard curves of each
primer pair in the qPCR had almost similar slopes, indi-
cating that GAPDH and receptor cDNAs were amplified
with the same efficiency (data not shown) [10]. The
values of each slope were close to 3.3, meaning that the
amplification efficiencies were almost optimal. There
was no significant contaminating nucleic acid in blank
control samples.
The ETB receptor mRNA expression remained unaltered
after SHS exposure as compared to control (Figure 2A).
The protein level of ETB receptor relative to b-actin was
0.10 ± 0.03 in fresh air exposed rats, and 0.11 ± 0.04 in the
SHS exposed group (Figure 2B). These results were in
concert with the functional myograph studies.
The mRNA level for the ETA receptor relative to
GAPDH was significantly elevated after SHS in cerebral
arteries (Figure 2A). The level of ETA receptor protein
was 0.12 ± 0.02 relative to b-actin in the fresh air group
and enhanced to 0.79 ± 0.02 after SHS (Figure 2B; P <
0.01). Taken together, the results demonstrate that SHS
induces ETA receptor upregulation.
MAPK signal pathway studies
To investigate the underlying intracellular signal trans-
duction mechanisms associated with the SHS-induced
increase in ETA receptor expression, we first examined
the mRNA levels of several key protein kinases such as
Raf-1, ERK1, ERK2, p38a and JNK1 by real-time PCR.
The results showed that SHS increased mRNA levels of
Raf-1, ERK1 and ERK2 as compared to the fresh air
group. SHS had no effect on p38a and JNK1 mRNA
levels (Figure 3A).
In addition, we examined the phosphorylated (p)-Raf-1,
p-ERK1/2, p-p38 and p-JNK, and their total protein
expressions by Western blot in rat cerebral vessels. Total
Raf-1 and ERK1/2 protein were unaltered in the SHS
group compared to fresh air group. The phosphorylated
protein of Raf-1 was enhanced to 0.31 ± 0.08 (SHS) from
0.06 ± 0.01 (Fresh air; P < 0.05, Figure 3B). The level of
p-ERK1/2 protein relativet oE R K 1 / 2i nf r e s ha i ra n d
SHS animals were 0.16 ± 0.04 and 0.51 ± 0.10 (P <0 . 0 1 ) ,
respectively (Figure 3C). In contrast, the protein level of
p-p38 was 0.14 ± 0.02 (fresh air) and 0.16 ± 0.03 (SHS);
the level of p-JNK protein was 0.21 ± 0.04 (fresh air) and
0.19 ± 0.03 (SHS). We did not find any significant differ-
ence in protein expression of p-p38 and p-JNK between
fresh air and SHS groups. The results show that SHS
induces enhanced expression of cerebrovascular ETA
receptors via the Raf/ERK1/2 activation, but does not
appear to involve JNK or p38 pathways in the present
experimental conditions.
Effect of GW5074 on SHS-induced effects
In order to further understand the role of Raf/ERK/MAPK
signal pathway, we studied the inhibitory effect of daily
GW5074 administration on SHS-induced responses. The
results showed that the Raf-1 and ERK1 mRNA levels in
cerebral arteries were significantly lower after GW5074
treatment in SHS exposed animals (Figure 3A). ERK2
mRNA showed a somewhat lower level after inhibition
which was not different from the SHS group (P > 0.05).
The mRNA levels of other protein kinases (p38a and
JNK1) remained unaltered by GW5074 treatment in SHS.
Western blotting confirmed the mRNA results. There was
a significant decrease in the p-Raf-1 and p-ERK1/2 protein
level after GW5074 treatment as compared with that of
SHS (Figure 3B-C). The p-p38 and p-JNK proteins
remained unchanged between the smoke exposure and
treatment groups. The protein level of p-p38 was 0.16 ±
0.03 (SHS) and 0.18 ± 0.04 (SHS+GW); the level of p-JNK
protein was 0.19 ± 0.03 (SHS) and 0.23 ± 0.05 (SHS+GW),
respectively.
SHS or SHS with the Raf-1 inhibitor did not modify
the weak S6c-induced contraction after 8 weeks of SHS
combined with daily administration of GW5074 (Figure
1A). In contrast, treatment with GW5074 markedly
attenuated SHS-induced enhanced cerebral vasocon-
striction elicited by ET-1 at ETA receptors (Figure 1B).
The Emax of the ET-1 induced concentration-contrac-
tile curve in GW5074 treatment group was now the
same as that seen in rats exposed to fresh air for 8
weeks (Table 2).
Table 2 Effect of 8 week SHS on rat cerebral artery contractions induced by K
+, S6c and ET-1
Group n K
+ (mN) S6c ET-1
Emax (% of K
+) pEC50 Emax (% of K
+) pEC50
Fresh air 10 5.7 ± 0.42 8.7 ± 0.5 9.32 ± 0.13 124 ± 9 8.86 ± 0.15
SHS 9 6.1 ± 0.53 9.5 ± 0.6 9.54 ± 0.19 160 ± 11* 8.97 ± 0.11
SHS+GW 8 6.3 ± 0.58 9.7 ± 0.9 9.37 ± 0.14 132 ± 15 8.77 ± 0.13
The cerebral arteries were from groups of fresh air, SHS and SHS treatment with GW5074 for 8 weeks. K
+-induced responses were expressed as absolute values
of contraction (mN). S6c and ET-1-induced responses were expressed as percentage of K
+-induced contraction. *P < 0.05 versus fresh air group. Emax, maximal
contraction; pEC50, negative logarithm of the concentration that produces 50% of the maximal contractile effect; SHS, secondhand smoke exposure; GW, GW5074
(0.5 mg/kg).
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Page 3 of 10Figure 1 Contractile responses induced by S6c (A) and ET-1 (B) in rat cerebral arteries. The cerebral arteries were isolated from groups of
fresh air, SHS and SHS treatment with GW5074. Contractions were induced by cumulative application of S6c or ET-1 (n = 8-10). *P < 0.05, **P <
0.01 versus fresh air group,
#P < 0.05 versus SHS group; SHS, secondhand smoke exposure; GW, GW5074 (0.5 mg/kg).
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Page 4 of 10Figure 2 The levels of ETB and ETA receptor mRNA (A) and protein (B) expression in rat cerebral arteries. The cerebral arteries were
isolated from groups of fresh air, SHS and SHS treatment with GW5074. Receptor mRNA content was examined by real-time PCR (n = 5-8) and
the protein level was examined by Western blot (n = 5-6). *P < 0.05, **P < 0.01 versus fresh air group,
#P < 0.05 versus SHS group; SHS,
secondhand smoke exposure; GW, GW5074 (0.5 mg/kg).
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Page 5 of 10The mRNA and protein levels of ET receptors were also
determined after treatment with Raf-1 inhibitor. The ETB
receptor mRNA and protein levels were unchanged in the
inhibitor group as compared to SHS or fresh air groups
(Figure 2A-B). The mRNA level of ETA receptors was sig-
nificantly reduced after inhibition of Raf/ERK/MAPK in
the SHS group (Figure 2A). The protein level of ETA
receptor was lower in the GW5074 treatment group but
did not reach statistical significance (Figure 2B).
Discussion
This is the first clear-cut demonstration that SHS
increases the level of contractile ETA receptors in cerebral
arteries via activation of the Raf/ERK/MAPK pathway. It
is known that smokers or SHS exposure subjects have an
increased risk to fall ill in stroke. However, the mechan-
isms behind this are poorly understood. Here, we show
that the upregulation of ETA receptors with increased
receptor-mediated vasoconstriction in the cerebral arteries
Figure 3 The level of MAPK molecule (ERK1, ERK2, p38a and JNK1) mRNA expression in rat cerebral arteries (A). Activation of Raf-1
protein expression in rat cerebral arteries (B). Activation of ERK1/2 protein expression in rat cerebral arteries (C). The cerebral arteries were
isolated from groups of fresh air, SHS and SHS treatment with GW5074. The key MAP kinases mRNA was relative to GAPDH (n = 5-6); and the p-
Raf-1 and p-ERK1/2 protein were relative to Raf-1 or ERK1/2 level (n = 5). *P < 0.05, **P < 0.01 versus fresh air group,
#P < 0.05 versus SHS group,
ns not significant; SHS, secondhand smoke exposure; GW, GW5074 (0.5 mg/kg).
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related stroke. Specific inhibition of the Raf/ERK/MAPK
pathway abolished the upregulation of ETA receptors in
cerebral arteries of SHS exposed rats, while the other main
MAPKs p38 and JNK were not affected.
Accumulating evidences indicate that both active and
passive cigarette smoking are strongly associated with the
origin and the development of stroke [1,13]. There is a
clear relation between smoking-related stroke risk, the
dose-response relationship existence, and the costs of the
smoke exposure on individuals and society [24]. The pre-
sent study was designed to imitate the manner of SHS
exposure in man. It was found that animals required to be
exposed to SHS for 8 weeks (200 min/day of passive
smoke from the lit cigarette) to show ETA receptor
changes. Two or 4 weeks of SHS did not alter ET recep-
tor-mediated vasoconstriction in cerebral arteries. After 8
weeks of SHS exposure there was a significant increase in
cerebral artery contraction mediated by ETA receptors.
Basically, enhanced cerebral vasoconstriction mediated by
receptors can be attributed to upregulated (presence of
more) receptors and/or increased sensitivity of cerebral
vessels in response to receptor agonist [22,25]. Since the
contractile response mediated by receptors is considered a
reflection of receptor expression in cerebral arteries, the
receptor-mediated vasoconstriction is in accord with
enhanced receptor levels. In agreement, results of mRNA
and protein expressions of ETA receptors were in support
of our hypothesis of more receptors. These results reveal
that SHS upregulates the ETA receptor via at r a n s c r i p -
tional mechanism. SHS exposure did not alter ETB recep-
tor expression or the receptor-mediated contraction. This
implies the method to culture cerebral arteries with
tobacco extracts in vitro [14] differs from passive smoke
exposure in the whole animal in vivo. Furthermore, SHS
did not alter the K
+ induced contraction in any group
which further suggests specificity in the receptor upregula-
tion process.
It is known that the ET-1 levels in blood and CSF are
increased in stroke; this may be further translated to an
enhanced receptor-mediated contraction in cerebral
arteries [26]. Transcriptional upregulation of ETA and
ETB receptors has been reported in rat cerebral arteries
after using some injury models like experimental cerebral
ischemia and organ culture [10,19,27,28]. In all cases, the
receptor upregulation occurred in the smooth muscle
cells. The similar findings were confirmed in cerebral
vessels from ischemic stroke patients [29,30]. Conse-
quently, we believe that the ETA receptor was also
increased in smooth muscle cells in the present study.
Currently it reveal that SHS induces enhanced expression
of ETA receptor mRNA and protein in cerebral arteries;
this implies an important role in SHS-associated stroke.
The significance remains to be tested in SHS-exposed
animals using experimental stroke models; possibly they
may show larger infarcts after an experimental stroke.
MAPKs have an important role in cerebrovascular
receptor plasticity [3]. Particularly for ERK1/2, it located
downstream of a dynamic chain of the kinases and is
considered mainly mitogenic and has a predominant role
in growth factor receptor signaling. We have demon-
strated activation of ERK1/2 in cerebral arteries after
MCAO and cerebral ischemia [18,21]. On this basis, the
involvement of ERK1/2 pathway was assessed in the con-
tractile receptor upregulation in artery culture [27].
Recently, a number of MAPK inhibitors were used to
compare their ability to prevent the upregulation of var-
ious cerebrovascular vasoconstrictor receptors during
o r g a nc u l t u r e[ 1 4 , 3 1 ] .I nt h ep r e s e n ts t u d yw ed e m o n -
strated SHS exposure induced ERK1/2 signaling activa-
tion by enhanced ERK1/2 phosphorylation. Moreover, we
showed that SHS upregulated ETA receptors in rat cere-
bral arteries. It means SHS-induced ETA upregulation
occurs through ERK1/2 activation. Meanwhile, we used a
Raf-1 inhibitor GW5074 and confirmed that it is Raf/
ERK1/2 signaling involved in the SHS-induced receptor
changes, but not JNK or p38 pathway. This hypothesis is
also supported by our recent in vitro discovery in cere-
bral arteries exposed to lipid-soluble smoke particles [28].
Raf-1 is associated ubiquitously in the Raf/MEK/ERK
pathway. Raf phosphorylates MEK1/2, which in turn
phosphorylates and activates ERK1/2 and then leads to
activation of transcription factors [32]. The ERK1/2 path-
way is a major effector of Raf. Transient activation of
Raf-1 contributes to alterations in smooth muscle cell
function, such as enhanced contraction and proliferation,
whereas sustained activation results in differentiation via
the regulation of various ERK substances [33]. We chose
the Raf-1 inhibitor GW5074 to further demonstrate the
involvement of ERK in the ET receptor upregulation
after SHS. The specificity and efficacy of GW5074 for
inhibiting Raf-1 in-vivo has been established in previous
studies [32,33]. Lakey et al. and Chin et al. reported that
GW5074 is a potent Raf-1 inhibitor and examined the
effect of GW5074 on purified Raf-1 and confirmed that
GW5074 selectively inhibits Raf-1 in vivo. In the present
study, GW5074 attenuated the SHS-induced elevated
cerebral artery contraction as well as increased mRNA
mediated by ETA receptors. This strongly supports that
SHS induces ETA receptor upregulation via the Raf/ERK/
MAPK pathway. We demonstrated the mRNA of Raf-1
and ERK1/2 was increased after SHS, but the total Raf-1
or ERK1/2 proteins were not changed. We think the for-
mer measurement reflects steady state and thus that may
also be other changes such as in degradation or mRNA
stability.
The enhanced phosphorylation of Raf-1 and ERK1/2
suggests the Raf/ERK1/2 pathway has been activated.
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phorylation of transcriptional regulation. Currently, Raf-
1 inhibitor GW5074 reduced phosphorylation of ERK1/
2 as well as Raf-1. The GW5074-induced declined phos-
phorylation of ERK1/2 should be attributed to the
upstream inhibition of ERK1/2. However, the reason to
explain the reduced Raf-1 phosphorylation is not sure.
We think it may be some upstream influences or feed-
back mechanisms when blocking Raf-1 activity by
GW5074. It could be a partial reason for decreased Raf-
1 phosphorylation. Moreover, we performed in vivo
treatment in the animals. It may also be some possible
indirect effects of GW5074 that altered Raf-1 phosphor-
ylation when administrated with the inhibitor in vivo.
However, the overall data agree with the involvement of
Raf/ERK/MAPK in SHS.
Conclusions
The present study is the first to show that passive
smoke exposure upregulates ETA,b u tn o tE T B recep-
tors, in rat cerebral arteries. The upregulation of ETA
receptors occurs via activation of the Raf/ERK/MAPK
pathway. This mechanism may provide new options for
treatment of SHS-associated cerebrovascular diseases.
Methods
Animals
Male Sprague-Dawley rats (8-weeks old) were provided
by the Animal Center of Xi’an Jiaotong University Col-
lege of Medicine (China). All animal procedures were
approved by the Animal Ethics Committee of Xi’an Jiao-
tong University.
Passive cigarette smoke exposure model
Animals were exposed for 2 weeks, 4 weeks or 8 weeks to
SHS or fresh air (control). In a preliminary study, we did
not find significant difference of cerebral contractility
mediated by ET receptors in the 2 or 4 weeks groups.
Therefore, these data are only mentioned briefly below. In
the subsequent study, 30 rats were randomly divided into
3 groups of 10 rats in each group are exposed for 8 weeks:
(i) fresh air exposure injected with saline vehicle; (ii)
smoke exposure injected with saline; (iii) smoke exposure
and treatment with GW5074 (0.5 mg/kg, i.p.). The rats
were exposed to cigarette smoke from commercially avail-
able filter cigarettes (Marlboro, 1.0 mg of nicotine and
12 mg of tar content) in a plastic chamber (115 × 50 ×
65 cm; 0.37 m
3). Each cigarette was freely burning for
15 min, then the cigarette smoke was allowed to diffuse in
the whole chamber for another 25 min. Fresh air was then
present for 20 min after every SHS exposure [34]. For
each smoke exposure, 2 cigarettes were lit simultaneously.
The rats were repeatedly exposed to the smoke 5 times
every day for up to 8 weeks. The total SHS exposure was
therefore 200 min/day. The rest of time animals were
exposed to fresh air. In the fresh air group, rats were
exposed only to room air. For the treatment group,
GW5074 was administrated to the animals once every day
for 8 weeks in addition to the same condition of SHS
exposure. The dosage of GW5074 was based on a previous
study [32,34]. This exposure type may resemble SHS expo-
sure and that the level of nicotine in the animals compare
well with at seen in plasma of human smokers.
Harvest of cerebral arteries
After the exposure period (fresh air, SHS and SHS trea-
ted with GW5074), rats were anesthetized with CO2,
sacrificed in a cage filled with dry ice and then decapi-
tated. The basilar arteries, middle cerebral arteries and
circle of Willis arteries were dissected free from the
brain and chilled in ice-cold bicarbonate buffer solution
[11]. Some of the basilar arteries were cut into cylindri-
cal segments for in vitro pharmacology studies. The
remaining part of the basilar arteries, the middle cere-
bral arteries and the circle of Willis arteries were snap
frozen at -80°C for real-time PCR and Western blot
examinations.
Cerebral artery contractile function studies
The myograph experiments were performed at the Depart-
ment of Pharmacology, Jiaotong University, while the other
experiments were done in the Lund University. Wire myo-
graph (Danish Myo Technology A/S, Aarhus, Denmark)
was a sensitive system for recording the vessels contractile
properties. The cerebral artery segments were mounted on
two thin wires in temperature controlled (37°C) myograph
baths containing 5 mL bicarbonate buffer solution.
Detailed method has been described before [10,35]. The
viability of arterial segments was then tested by exposure
to a potassium-rich (63.5 mM K
+) buffer solution.
Concentration-response curves were obtained by the
cumulative administration of the selective ETB receptor
agonist S6c, and the combined ETA and ETB receptor
a g o n i s tE T - 1 .T os t u d yE T A receptor-mediated contrac-
tion, the experiment started with the desensitization of
the ETB receptors by performing a concentration-
response curve to S6c firstly [36]. The ETA receptor and
the ETB receptor antagonists (FR139317 and IRL2500)
were used to show receptor specificity [22,23].
Real-time PCR
Total RNA was extracted from cerebral vessels using
RNeasy Mini kit, following the supplier’s instruction
(Qiagen, Valencia, USA). Details were described before
[10]. Reverse transcription of total RNA to cDNA was
performed using the TaqMan Reverse Transcription
Reagents (Applied Biosystems, Branchburg, USA) in a
Perkin Elmer 2400 GeneAmp PCR system (Perkin Elmer,
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Page 8 of 10MA, USA). Real-time PCR was performed using the Gen-
eAmp SYBR
® Green kit in a GeneAmp 7300 Sequence
Detection System Specific primers for the ETA and ETB
receptors were designed as follows: ETA receptor, for-
ward: 5’-GTC GAG AGG TGG CAA AGA CC-3’,E T A
receptor, reverse: 5’-ACA GGG CGA AGA TGA CAA
CC-3’,E T B receptor, forward: 5’-GAT ACG ACA ACT
TCC GCT CCA-3’,E T B receptor, reverse: 5’-GTC CAC
GAT GAG GAC AAT GAG-3’.P r i m e r so fE R K 1 ,E R K 2 ,
JNK1 and p38a protein kinases genes were purchased
from RT
2 qPCR Primer Assay. As an endogenous stan-
dard, the primers of glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) were designed as follows: GAPDH,
forward: 5’-GGC CTT CCG TGT TCC TAC C-3’,
GAPDH, reverse: 5’-CGG CAT GTC AGA TCC ACA
AC-3’. The mRNA content was calculated relative to the
amount of GAPDH. These have been analyzed previously
and verified using 3 different standards [10].
Western blot
The protein of cerebral vessels was extracted as described
before [37]. After gel eletrophoresis and protein transfer,
membrane was then blocked in 5% non-fat milk. Subse-
quently, the membrane was incubated at 4°C overnight
with primary antibodies: rabbit anti-ETA, rabbit anti-ETB,
rabbit anti-p-Raf-1, anti-p-ERK1/2, rabbit anti-p-JNK1/2/
3, rabbit anti-p-p38, mouse anti-b-actin, rabbit anti-Raf-1
or mouse anti-ERK1/2. Then, membranes were incubated
with horseradish peroxidase-conjugated anti-rabbit or
anti-mouse secondary antibodies. Finally, membranes
were developed and visualized using a Fujifilm LAS-1000
Luminescent Image Analyzer (Fujifilm, Stamford, USA)
and the band intensity was quantified by Image Gauge
Version 4.0.
Statistical analysis
All data are expressed as means ± SEM and n refers to the
number of rats. Unpaired Student’s t-test was applied to
compare two sets of data. One-way analysis of variance
(ANOVA) with Dunnett’s post-test was used for compari-
son of more than two data sets. Two-way ANOVA with
Bonferroni’s post-test was used to compare the two corre-
sponding data points at each concentration of the two
curves. P < 0.05 was considered as statistical significance.
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